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The use of ketamine as a recreational drug, particularly among teenagers, has increased dramatically in
the past few years in Taiwan. Its effects on the central nervous and cardiovascular systems are well
characterized, but an increasing amount of evidence demonstrates its association with urinary tract
pathologies. Chronic ketamine use has been associated with severe ulcerative cystitis. Symptoms and
signs of long-term ketamine abuse include: hematuria; increased voiding frequency; urgency; bladder
pain; dysuria; nocturia; decreased bladder capacity; urothelial ulceration, and eosinophil inﬁltration.
Vesicoureteral reﬂux and renal function impairment may also occur in heavy ketamine users. How ke-
tamine use produces these symptoms is not clear. Dysregulation of purinergic neurotransmission has
recently been found to play a role in the detrusor overactivity in ketamine-induced bladder dysfunction.
The goal of treatment is to prevent deterioration of the renal function and indeed offer the possibility of
symptom resolution. Currently, ketamine cessation is the only effective treatment modality, but the
effect is likely to be dependent on the severity and duration of the abuse. Anticholinergic agents fail to
relieve the symptoms induced by chronic ketamine use. Intravesical hyaluronan solution instillation may
help improve the symptoms, but more clinical studies are required to provide evidence of the effec-
tiveness. A multidisciplinary treatment team of doctors, psychiatrists, nurses, therapists, and clinicians
will facilitate best practice management of patients with ketamine-associated cystitis.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Ketamine is a phencyclidine derivative that was ﬁrst used in
humans in 1965, and has been clinically used as a quick-acting
anesthetic drug since the 1970s.1 Its receptor binding has not
been fully elucidated but includes an antagonist action at N-
methyl-D-aspartate receptors throughout the central and periph-
eral nervous system. Ketamine has recently become more widely
used as a recreational drug, especially in night clubs and dance
parties.2 Many young people start using ketamine as teenagers.3
Ketamine has been found to cause a variety of addictive effects,
including altered sensations, out of body experiences, and a
euphoric rush, in addition to several negative effects, including
increased heart and respiratory rates, nausea and vomiting, con-
vulsions, temporary paralysis, and hallucinations. Unique to keta-
mine, recreational users describe a near-death experience,
including buzzing, ringing, and whistling sounds, a sense of traveltment of Surgery, Tri-Service
ipei, Taiwan, ROC.
ciation. Published by Elsevier Taiwthrough a dark tunnel into a light at high speed, and intense vi-
sions.4,5 Despite the negative effects, very few deaths have been
associated with ketamine overdoses.6 Recently, an increasing
amount of evidence has demonstrated ketamine’s association with
chronic ulcerative cystitis, which causes severe lower urinary tract
symptoms (LUTS), such as increased voiding frequency, urgency,
dysuria, and nocturia.7,8 How ketamine use produces these symp-
toms is not known; others have postulated that accumulation of
ketamine and/or its metabolites may induce an inﬂammatory or
autoimmune response within the bladder wall.7 Here we review
the recent literature regarding the urological impact of ketamine
abuse and its treatment.
2. Epidemiology
The precise prevalence of recreational, nonmedical ketamine
use is unknown. A recent government report in Taiwan has indi-
cated that the percentage of ketamine increased dramatically in the
past few years, making it one of the most popular drugs of inves-
tigation ﬁndings. The age of young people tested positive for ke-
tamine was less than a median of 30 years, indicating that the
groups abusing ketamine are getting younger. Moreover, the vol-
ume of seizures of street ketamine in Taiwan has increased froman LLC. Open access under CC BY-NC-ND license.
Table 1
Comparison of the symptoms and signs of ketamine-associated cystitis and inter-
stitial cystitis/painful bladder syndrome.
Symptoms or signs Ketamine-associated
cystitis
Interstitial cystitis/painful
bladder syndrome
Pathogen Ketamine Unknown
Pathogenesis Unknown Neuroimmunoendocrine
disorder
Symptoms
Frequency Very common Very common
Urgency Very common Not common
Nocturia Very common Very common
Suprapubic pain Very common Very common
Hematuria Common Occasional
Signs
Pyuria Common Rare
Epithelial inﬂammation
and neovascularization
of the bladder
Complications
Very common Very common
Ureteral stenosis, VU
reﬂux, and renal
function impairment
Common after long
term or high dose
ketamine use
Occasional
E. Meng et al. / Urological Science 24 (2013) 113e116114916 kg in 2009 to 1187 kg in 2010.9 In Australia, lifetime use of
ketamine was reported by 1% of Australians aged 14 years or older,
with 0.3% reporting recent use. Prevalence of ketamine use was
highest among those aged 20e29 years.10 Only few people used
ketamine in their 40s.11,12 A recent study assessing the prevalence
of urinary symptoms in a large cohort of nonetreatment-seeking
ketamine users revealed that 26.6% of recent ketamine users
experienced urinary symptoms. Urinary symptoms were signiﬁ-
cantly related to both dose of ketamine used and frequency of ke-
tamine use.13 Currently, no gender bias has been found in
ketamine-associated cystitis (KC),7 although some series have re-
ported a slight male predominance in ketamine abuse.113. Pathophysiology
The pathogenesis of bladder dysfunction under this condition
is still not clear. It has been proposed that it may result from the
two active metabolites of ketamine: norketamine and hydrox-
ynorketamine.7 Recent studies have shown that ketamine and its
active metabolites can be measured in high quantities in the
urine of patients using ketamine.14 It is conceivable that ketamine
and its active metabolites may accumulate in the urine and
induce signiﬁcant bladder irritation. Chu et al7 postulated the
following pathophysiological mechanisms that might account for
the urinary tract damage: (1) the high concentration of ketamine
and its metabolites in the urine might cause direct toxic effects
on the bladder interstitial cells, causing a signiﬁcant chronic
submucosal inﬂammatory response; (2) ketamine and its me-
tabolites might induce microvascular changes in the bladder
and possibly the kidney, causing endothelial cell injury of
microvessels and leading either to compromised intrinsic
microcirculation, or decreased microvascular density in the sub-
endothelium; (3) an autoimmune reaction to the bladder uro-
thelium and submucosa triggered by the presence of circulating
ketamine or urinary ketamine and its metabolites; and (4)
bacteriuria as the possible cause for the cystitis and papillary
necrosis is unlikely in these patients, compared with other
possible causes as described above.
Recent pathological research on the urinary bladder of ketamine
addiction employing mice reveals mononuclear inﬁltration, similar
to that of the clinical situation of interstitial cystitis/painful bladder
syndrome (IC/PBS; Table 1). There was also a possible decrease inthe cholinergic neurons in the urinary bladder of the ketamine
treated animals.15 A mouse model of ketamine abuse was devel-
oped recently and showed that dysregulation of purinergic
neurotransmission may be the cause of detrusor overactivity in
ketamine-induced bladder dysfunction.16 Chuang and colleagues17
state that ketamine also initiated the upregulation of COX-2 and
iNOS and eNOS expression, which may play an important role in
contributing to ketamine-induced alterations in micturition pat-
terns and ulcerative cystitis. Bladder tissue from KC and IC/PBS
patients was found to have similar characteristics of defective
junctional protein, increased suburothelial inﬂammation, and
increased urothelial cell apoptosis, although decreased expression
of E-cadherin, a Ca2þ-dependent, transmembrane cell adhesion
molecule, and increase of apoptosis were more severe in KC blad-
ders than IC/PBS.18
4. Clinical presentation
A recent study has demonstrated that using ketamine for at least
a 2-year habit of three or more times a week is associated with
lower urinary tract dysfunction and that these symptoms may
persist for up to 1 year after the cessation of drug use.19 The
symptoms of KC include a variety of LUTS mainly irritative in na-
ture. Typically, patients complain of nocturia, urgency, extreme
frequency, bladder pain, and intractable dysuria. Gross hematuria is
also a frequent symptom in those suffering from ulcerative cystitis.
Tsai et al20 reported that symptoms appeared after 1 month of
starting the usage and became severe by the end of 1 year. Flank
pain may occur due to hydronephrosis secondary to ureteral
stricture or vesico-ureteric reﬂux (VUR).21
5. Investigation
Symptom questionnaires such as O’Leary’s IC symptom scales,
American Urological Association’s symptom score for benign
prostatic hyperplasia and overactive bladder symptom scores, may
help to evaluate the severity of the symptomatology and monitor
disease progression or regression with or without treatment,
although they have not been validated as diagnostic criteria. Nor-
mally, urinalysis and urine cultures show nonbacterial pyuria on an
initial assessment of the mid-stream urine sample. Cystoscopy re-
veals various degrees of epithelial inﬂammation and neo-
vascularization of the bladder. Severe cases may present petechial
hemorrhages and ulcers of the bladder mucosa, as classically
described in patients with IC.7 Urodynamically, either detrusor
overactivity or decreased bladder compliance with, or VUR was
detected to some degree in those patients with KC7,8,20,22 (Fig. 1). It
has been postulated that VUR is a secondary event to the severely
contracted bladder with high detrusor pressure. The functional
bladder capacity is commonly <150 mL.7 Chen et al23 reported that
patients with KC have worse symptom scores, poor quality of life,
and signiﬁcant decrease of urodynamic parameters compared to
those with IC/PBS.
Renal ultrasonography in half of the patients showed either
unilateral or bilateral hydronephrosis on the initial assessment;
papillary necrosis suggestive of transmural necrosis has also
been reported.7 It has been demonstrated that retrograde pye-
lography illuminated bilateral hydronephrosis and “walking-stick
ureters”, characterizing segmental beading from ureteral stric-
tures and straightening of both ureters in a heavy ketamine
abuser.21 Pathological changes of bladder demonstrated denuded
and focal reactive urothelium. The lamina propria showed
granulation tissue and congested vessels, inﬁltrated predomi-
nantly by lymphocytes, mast cells and a variable number of
eosinophils.7,20
Fig. 1. Pressure-ﬂow study of a 21-year-old man who used ketamine for 6 years revealed small bladder capacity and detrusor overactivity (arrowheads).
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The goal of treatment is to prevent deterioration of the renal
function and indeed offer the possibility of symptom resolution.
Currently, ketamine cessation is the only effective treatment mo-
dality; however, the effect is likely to be dependent on the severity
and duration of the abuse.7,20,24 The bladder function of patients
with near-normal cystometric bladder capacities has been shown
to return to normal after stopping or reducing ketamine abuse.7
Patient compliance has previously been shown to be poor in pa-
tients suffering addiction and failure to abstain may lead to disease
progression.7,25 Various treatment regimens have been used to
treat the patients such as antibiotics, oral nonsteroidal anti-
inﬂammatory drugs, steroids, anticholinergic therapy,7 and
hydrodistention of the bladder20; however, all have failed to pro-
vide signiﬁcant and lasting improvement. It is still not clear
whether full symptomatic resolution will not be achieved in more
advanced cases with severely reduced bladder capacity and
compliance and consequent hydronephrosis. Because the clinical
features of ketamine-associated cystitis are very similar to IC, the
possible etiology of impaired epithelial impermeability leading to
leakage of the glycosaminoglycan layer has led to the use of oral
pentosan polysulphate (Elmiron) and intravesical instillation of
hyaluronic acid (Cystistat) in the treatment of IC. Elmiron, a low
molecular weight heparin-like compound, has been tried to rebuild
the glycosaminoglycan layer of the damaged urothelium and a few
patients experienced symptom relief after treatment.8 Tsai et al20
have reported that all patients who had hyaluronic acid instilla-
tion had symptomatic relief, especially in relieving the bladder
pain, frequency, and hematuria, but long-term follow-up is needed.
It is unclear whether it is purely attributable to the abstinence,
therapy, or both. These two options may provide a sense of direc-
tion, but longer follow-up is needed.As with interstitial cystitis or a neurogenically induced spas-
modic bladder, augmentation enterocystoplasty or cystectomy
with conduit diversion should be considered if conservative
treatment fails to relieve the symptoms and preserve renal func-
tion.26 However, if the patient continues to abuse ketamine, they
should be warned that ﬁbrotic change of the urinary reservoir may
occur.
7. Conclusions
Chronic ketamine use has been associated with severe ulcera-
tive cystitis, which may lead to bladder contracture and dysfunc-
tion. After long-term ketamine use, patients may suffer from LUTS,
including hematuria, increased voiding frequency, urgency,
dysuria, and nocturia. Cystoscopy and urodynamic study may
reveal urothelial ulceration and reduced bladder capacity and
compliance. Histology of the ketamine bladder showed inﬁltrations
of granulocytes (predominantly eosinophils) and mast cells within
the bladder tissue. The etiology of ketamine-associated cystitis is
still not clear. The goal of treatment is to prevent deterioration of
the renal function and indeed offer the possibility of symptom
resolution. Currently, ketamine cessation is the only effective
treatment modality, but the effect is likely to be dependent on the
severity and duration of the abuse. A multidisciplinary approach
promoting harm reduction, cessation, and early referral is needed
to manage individuals with KC to avoid progression to severe and
irreversible urological pathologies.
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